Can a new drug help keep aggressive lung cancer at bay?

This study looked back at the medical records of 45 patients to see if adding the drug durvalumab after they finished standard chemotherapy and radiation helped control their limited-stage small-cell lung cancer for a longer time. Researchers wanted to understand the real-world effectiveness and safety of this treatment approach by checking how long patients lived without their cancer getting worse. The study did not test a new treatment but analyzed how patients already treated at one hospital fared.